---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Miglustat"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Miglustat. Topics: Guideline recommendation: miglustat for all patients with a confirmed diagnosis, Candidates for miglustat and exclusions in GeneReviews, Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States, Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort, and 7 further topics. 11 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/miglustat"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Miglustat

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Miglustat

<a id="topic-2.2.2.1.1-1"></a>

### Guideline recommendation: miglustat for all patients with a confirmed diagnosis

> “Miglustat, a substrate reduction therapy, is licensed as a disease‐modifying medicine to treat the neurological manifestations of patients with NPC disease.”
> “In some patients, miglustat has been shown to attenuate disease progression and improve survival.”
> “Statement #15: All patients with a confirmed diagnosis of NPC should be considered for miglustat therapy.”
> “Strength of recommendation: 1”
> “Level of evidence: B”
> “Expert's opinion: completely agree (44.83%), mostly agree (44.83%), partially agree (10.34%), partially disagree (0.00%), mostly disagree (0.00%), and completely disagree (0.00%).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.1-2"></a>

### Candidates for miglustat and exclusions in GeneReviews

> “Thus, in countries where it is an approved therapy, individuals with a confirmed diagnosis of NPC should be considered for miglustat therapy, except individuals with NPC who:”
> “Have advanced neurologic disease / dementia;”
> “Have another life-threatening illness and an estimated life span <1 year;”
> “Have only spleen/liver enlargement.”
> “Note: Miglustat may produce loose stools and excessive flatus; these effects may be managed with dietary modification (by reduction or removal of lactose and other sugars).”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.1-3"></a>

### Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States

> “Miglustat is approved as treatment for neurological manifestations of NPC in Europe, Japan, and Canada.”
> “It works as a substrate reduction treatment to reduce accumulation of glycosphingolipid in the lysosome.”
> “Miglustat has United States (US) approval for some forms of Gaucher disease in adults (100 mg formulation) and in certain patients with Pompe disease (65 mg formulation).”
> “It is considered off-label in the US for NPC.”
> “The FDA has stated miglustat is considered standard of care in adult and pediatric patients with NPC by experts.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

> “Miglustat, an inhibitor of glucosylceramide synthase, has been approved to treat NPC in other countries; however, its use remains off-label in the United States.”
> “Miglustat has been shown to ameliorate neurological symptoms and extend survival but does not arrest disease progression.”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

> “Targeted therapies: Treatment for the neurologic manifestations of NPC can include miglustat (approved in several countries but not currently FDA approved for standalone treatment of NPC), arimoclomol (approved for use in combination with miglustat), and levacetylleucine (standalone treatment approved by FDA).”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.1-4"></a>

### Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort

> “Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis.”
> “Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months.”
> “12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area.”
> “The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression.”
> “At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028).”
> “Children showed an improvement in HSEM velocity of similar size at 12 months.”
> “Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years.”
> “The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.”

Source: [Patterson et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17689147/)

<a id="topic-2.2.2.1.1-5"></a>

### Open-label extension in adult and juvenile participants

> “All patients completing the randomized trial were allowed to continue treatment in a 12-month, non-controlled open-label extension.”
> “Mean horizontal saccadic eye movement velocity (HSEM-alpha) indicated improvement in the 12-month miglustat group, and stabilization in the 24-month group; swallowing was improved or stable in 86% and in up to 93%, respectively.”
> “Ambulation was stabilized in both the 12- and 24-month groups.”
> “In an exploratory disease stability analysis of prospective data on key parameters of disease progression (HSEM-alpha, swallowing, ambulation and cognition), 13/19 (68%) patients receiving >or= 12 months' miglustat therapy had stable disease.”
> “Among all patients receiving >or= 1 dose of miglustat (n=28), the most frequent adverse events were diarrhoea, weight decrease, flatulence and tremor.”

Source: [Wraith et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20045366/)

<a id="topic-2.2.2.1.1-6"></a>

### Open-label extension in children aged 4 to 12 years

> “Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase.”
> “Ten children completed 24 months' treatment.”
> “Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months.”
> “Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%).”

Source: [Patterson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/19822772/)

<a id="topic-2.2.2.1.1-7"></a>

### International NPC Registry: disability during continuous miglustat therapy by age at neurological onset

> “In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between September 2009 and October 2013; 92 patients received continuous miglustat therapy.”
> “Among 84 evaluable patients, 9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years) and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations.”
> “Progression of composite disability scores appeared highest among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset.”
> “Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable patients increased with age at neurological onset.”

Source: [Patterson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4462071/)

<a id="topic-2.2.2.1.1-8"></a>

### Survival with and without miglustat: pooled national cohorts and the NPC Registry

> “Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat.”
> “Miglustat treatment was associated with a significant reduction in the risk of mortality in neurological onset group patients (adjusted HR [95% CI] 0.510 [0.335, 0.777]; P < .01) (Figure 1A).”
> “The effect was consistent across all four age‐at‐neurological‐onset sub‐groups, with a trend that favoured miglustat treatment; all HRs were between 0.364 (late infantile patients) and 0.671 (early infantile patients).”
> “Results were statistically significant for late infantile patients (HR [95% CI] 0.364 [0.165, 0.801]; P < .05); statistical significance was not achieved in the remaining age‐at‐neurological‐onset sub‐groups (Figure 1A).”
> “Miglustat treatment was associated with a significant reduction in the risk of mortality in diagnosis group patients (HR [95% CI] 0.441 [0.293, 0.664]; P < .001) (Figure 2A).”
> “In conclusion, this study is the first exploratory analysis conducted in the largest pool of observational data for patients with NP‐C to date, treated in a real‐world setting and with a broad geographical representation.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.2.1.1-9"></a>

### Swallowing outcomes in a single-center cohort with neurological onset before age 15 years

> “Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression.”
> “In this cohort study of 50 individuals with Niemann-Pick disease, type C1 with neurologic disease onset before age 15 years, miglustat use was associated with stabilized swallowing function and reduced aspiration risk.”
> “Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001).”
> “Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).”

Source: [Solomon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489403/)

<a id="topic-2.2.2.1.1-10"></a>

### Infantile onset: French pediatric cohort treated in clinical practice

> “Twenty children were enrolled; 19 had NPC1 gene mutations and 1 had NPC2 gene mutations.”
> “Eight NPC1 patients had the early-infantile, eight had the late-infantile, and three had the juvenile-onset forms of NP-C.”
> “NP-C disability scale scores indicated either stabilization or improvement of neurological manifestations in 1/8, 6/8, and 1/3 NPC1 patients in these subgroups, respectively.”
> “Mild-to-moderate gastrointestinal disturbances were frequent during the first 3 months of miglustat therapy, but were easily managed with dietary modifications and/or anti-propulsive medication.”
> “Among early-infantile onset patients, a shorter delay between neurological disease onset and miglustat initiation was associated with an initial better therapeutic outcome in one patient, but miglustat did not seem to modify overall disease course in this subgroup.”

Source: [Héron et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3465012/)

<a id="topic-2.2.2.1.1-11"></a>

### Early infantile onset: French retrospective comparison of treated and untreated patients

> “Ten patients were included in the treated group (year of birth: 2006–2012), and 16 patients in the untreated group [born 1987–2005 (n = 15), 2012 (n = 1)].”
> “Miglustat therapy was started at a median age of 24.5 months (9–29) and median duration was 30 months (11–56).”
> “Gastrointestinal adverse events were reported in 7/10 patients on miglustat.”
> “All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy.”
> “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

> “Evidence for miglustat efficacy in pre/perinatal and early infantile cases remains limited”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
